Blueprint Medicines

@BlueprintMeds

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers

Cambridge, MA
Vrijeme pridruživanja: kolovoz 2014.

Tweetovi

Blokirali ste korisnika/cu @BlueprintMeds

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BlueprintMeds

  1. We’re committed to advancing for the community. Learn more about our clinical programs:

    Poništi
  2. 4. velj

    At in Milan, Italy, we’re thrilled to meet with key clinical leaders in and :

    Poništi
  3. 27. sij

    Do you or one of your loved ones have ? Learn more about the importance of mutational testing via Mutation Matters:

    Poništi
  4. 24. sij

    The is motivated to identify new drug targets that expand the possibilities of . Learn more about our science:

    Poništi
  5. 23. sij

    We seek to design precision therapies that target the underlying molecular basis of disease. Learn more about our approach:

    Poništi
  6. 17. sij

    Keith, our head of US Precision Medicine, will be speaking at next week about our efforts to fuel rapid advances in .

    Poništi
  7. 17. sij

    Sean and his team are committed to working closely with healthcare providers across the U.S. to help make a difference for patients with and .

    Poništi
  8. 16. sij

    is well-established as a genomically driven disease. Hear Maria, our senior medical director, explain the benefits of mutational testing for this cancer.

    Poništi
  9. 15. sij

    Since our company’s inception, we’ve focused on building a scalable research platform that could yield multiple precision therapies for a wide range of diseases. Learn more about our commitment to advancing :

    Poništi
  10. 15. sij

    Our annual mentoring program gives the opportunities to learn about functional areas different from their everyday roles. Check out our recent participants!

    Poništi
  11. 15. sij

    While a number of mutations may cause , KIT and PDGFRA are the primary drivers of the disease. Learn more:

    Poništi
  12. 14. sij

    Do you know the differences between immunohistochemical (IHC) staining, which support the diagnosis of , and mutational testing? Read more about both, courtesy of :

    Poništi
  13. 13. sij

    If you’re planning to start treatment, mutational testing can help determine the right therapy for your tumor type. Hear more from a clinical expert:

    Poništi
  14. 10. sij

    We’re dedicated to providing robust support throughout patients’ treatment journey. We developed our patient support program to reflect this commitment; read more here:

    Poništi
  15. 10. sij

    Our Medical Director Brenton highlights the benefits of , which aims to deliver the right treatment to the right patient.

    Poništi
  16. 10. sij

    We're gratified to bring a new treatment option to patient, which was made possible by the unwavering efforts of clinical investigators, trial participants, patient groups like & GIST Support International, members past & present, and many others.

    Poništi
  17. 9. sij

    Dr. Michael Heinrich from , who's an investigator in our clinical trials, highlights a new era of in GIST and the importance of mutational testing.

    Poništi
  18. 9. sij

    Tune in today at 4:30 p.m. ET for our live webcast to discuss our approval:

    Poništi
  19. 9. sij

    Today, we received approval for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor () harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Learn more:

    Poništi
  20. 9. sij

    looks forward to joining others in the industry next week at the 38th Annual J.P. Morgan Healthcare Conference. Hope you to see you in San Francisco!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·